Komori
SanBio (4592) · FactFirst stated

SB623 designated as a regenerative medical product for rare diseases

First written in FY2021. . Latest entry: FY2021.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Designation of SB623 as an orphan regenerative medical product for chronic traumatic brain injuryA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2021First statedAnnual report

    「In addition, in June 2020, the product was designated by the Ministry of Health, Labour and Welfare as an orphan regenerative medical product for the indication of improving sequelae of traumatic brain injury.」

    This filing was the first in the thread to report that SB623 for chronic traumatic brain injury had been designated by the Ministry of Health, Labour and Welfare as an orphan regenerative medical product.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for SanBio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
SB623 designated as a regenerative medical product for rare diseases | SanBio Company Limited (4592) | Komori